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Abstracts
Background: American tegumentary leishmaniasis (ATL) in Brazil is mostly caused by Leishmania (Viannia) braziliensis, with
known forms of the disease being cutaneous (CL), mucosal (ML) and disseminated (DL) leishmaniasis. The development of
the lesion in ATL is related both to the persistence of the Leishmania in the skin and to the parasite-triggered immune and
inflammatory responses that ensue lesions. In this context one factor with expected role in the pathogenesis is insulin-like
growth factor (IGF)-I with known effects on parasite growth and healing and inflammatory processes. In the present
study, we addressed the effect of IGF-I on intracellular amastigote isolates from CL, ML and DL patients within human
macrophage and we evaluated the IGF-I and IGF-binding protein-3 (IGFBP3) serum levels in patients presenting different
clinical forms and controls from the endemic area.
Methods: We evaluated biological variability in the responses of intracellular amastigotes of Leishmania isolates derived
from CL, ML, and DL patients from an area for ATL in response to IGF-I. Intracellular amastigote growth was evaluated using
the human macrophage cell line THP-1. Arginase activity in infected cells was evaluated quantifying the generated urea
concentration. Serum samples from patients and controls were assayed using chemiluminescent immunometric assay to
determine IGF-I and IGFBP3 levels.
Results: We observed an increase in intracellular parasitism upon IGF-I stimulus in 62.5 % of isolates from CL, in 85.7 %
from ML and only 42.8 % from DL cases. In DL, the basal arginase activity was lower than that of CL. We then evaluated
the IGF-I and IGFBP3 serum levels in patients, and we observed significantly lower levels in ML and DL than in CL and
control samples.
Conclusions: The data suggest that IGF-I is modulated distinctly in different clinical forms of tegumentary leishmaniasis.
IGF-I seemingly exerts effect on parasite growth likely contributing to its persistence in the skin in earlier phase. In addition
the decreased IGF-I serum levels may affect the modulation of inflammation and lesion healing in chronic phase. In view of
potential role of IGF-I in the pathogenesis of ATL we can speculate on therapeutic procedures taking into account the local
IGF-I level.
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Background
Human leishmaniasis caused by Leishmania (Viannia) bra-
ziliensis infection has a broad spectrum of manifestations
ranging from an asymptomatic infection to severe destruc-
tive ulcerated and inflammatory forms. The main clinical
forms are cutaneous leishmaniasis (CL), severe destructive
mucosal leishmaniasis (ML) and disseminated leishmaniasis
(DL) [1]. Some studies relate the different disease manifes-
tations to the intraspecific variability of L. (V.) braziliensis
not only in Brazil but also in Colombia [2–4] but not in
another study [5]. Besides, the presence of Leishmania
RNA virus 1 in L. (V.) braziliensis has been associated with
the development of ML but not in all ML cases [6]. There-
fore, the wide spectrum of manifestations caused by L. (V.)
braziliensis are still poorly understood.
It is known that the development of the lesion in tegu-
mentary leishmaniasis is related both to the persistence of
the Leishmania in the skin and to the parasite-triggered
immune and inflammatory responses that result in lesion
development [7, 8]. The Th1-type immune response con-
trols the parasite growth [7] but in chronic and severe le-
sions such as in mucosal leishmaniasis maintenance of the
supposedly beneficial immune response turn into chronic
and harmful process [9, 10].
In this context one of elements that may have role in
the pathogenesis is insulin-like growth factor (IGF)-I since
this factor has effect on both parasite growth [11] contrib-
uting to its persistence and on the healing and inflamma-
tory processes [12–14].
We have been studying the effect of IGF-I on Leish-
mania and in leishmaniasis, demonstrating its impact on
parasite growth and lesion development. IGF-I in cases of
L. (L.) amazonensis showed effects increasing the parasite
growth and cutaneous leishmaniasis lesion development
[11]. In Leishmania-macrophage interaction, IGF-I exerts
effect on Leishmania and host cells, mainly inducing argi-
nase expression and activity, leading to alternative activa-
tion of the macrophages interfering with inducible nitric
oxide synthase expression [11, 15, 16]. Because biological
effects may differ in other species and American tegumen-
tary leishmaniasis is mostly caused by L. (V.) braziliensis,
we analyzed the effect of this growth factor on this parasite
species. Then, we observed complex results related to the
source of the parasite isolates. IGF-I induced higher basal
arginase activity in promastigote isolates derived from pa-
tients with CL and DL; however, arginase activity was
already increased under basal conditions in isolates from
ML with no further increase upon IGF-I stimulus [17]. In
the present study, we addressed the effect of IGF-I on
amastigote forms of isolates from CL, ML and DL patients
within the THP-1 human macrophage lineage. We used
the macrophage lineage rather than macrophages derived
from peripheral blood monocytes to avoid variations in
cellular response in different individuals. We observed an
increase in intracellular parasitism upon IGF-I stimulus in
62.5 % of isolates from CL, in 85.7 % from ML and only
42.8 % from DL cases. Although we observed differences
among Leishmania isolates, they do not clearly explain
their different clinical manifestations.
Since in addition to the effect on parasite growth, IGF-
I has a pleiotropic effect on cell migration [18], wound
healing [12, 13] and inflammatory process [14], in the
present study, we evaluated the IGF-I and IGF-binding
proteins-3 (IGFBP3) serum levels in patients presenting
different clinical forms, CL, ML and DL and controls
from the endemic area. In this analysis, both IGF-I and
IGFBP3 levels decreased in ML and DL compared with
CL and controls. The data as a whole suggest that IGF-I
is modulated in different clinical forms of tegumentary
leishmaniasis, and IGF-I seemingly exerts effects on both
parasite growth likely contributing to its persistence in the
skin and its lower level affecting the modulation of inflam-
mation and lesion healing process. In view of potential role
of IGF-I in pathogenesis of tegumentary lesion develop-
ment we can speculate on therapeutic procedures consider-
ing local IGF-I level.
Methods
Study design and subjects
The patients included in this study were from Corte de
Pedra municipality, Bahia state, Northeastern Brazil, an area
with endemic tegumentary leishmaniasis mostly caused by
L. (V.) brasiliensis. The patients were approached at the
Corte de Pedra Health Post from 2002 through 2007. All
participants were volunteers and provided their individual
informed consent.
A leishmaniasis diagnosis was made based on a clinical
feature of these forms of leishmaniasis along with one of
the following criteria: parasite isolation or a positive skin
test for Leishmania soluble antigen and the presence of
histopathological findings suggestive of leishmaniasis.
Patients with CL had a typical ulcerative lesion in the
skin; ML patients had a metastatic mucosal nasal lesion
that was not contiguous with the primary cutaneous
lesion, and DL patients had polymorphic lesions (acnei-
form, papular, nodular and/or ulcerated) on two or more
parts of their body. The exclusion criteria included HIV
infection, diabetes mellitus and pregnancy. All patients
were evaluated before receiving therapy and during the
active disease. The ages ranged from 21 through 65 years.
One-hundred fourteen patients were studied, suffering
from CL (n = 65), ML (n = 20), DL (n = 29) and 14 en-
demic control subjects living in the same municipality.
The sera were stored at -70 °C until they were analyzed.
Isolates of L. (V.) braziliensis
The 22 isolates of Leishmania were obtained from patients
presenting with the following different clinical forms of the
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disease: cutaneous leishmaniasis (n = 8), mucosal leishman-
iasis (n = 7) and disseminated leishmaniasis (n = 7). The iso-
lates were obtained by aspirating the lesion, and the
samples were grown in tubes with biphasic medium (LIT/
NNN) supplemented with 10 % heat inactivated fetal calf
serum (FCS) (Cripion Biotechnology, Brazil) at 26 °C. The
parasite isolates were cryopreserved and expanded in
Schneider’s insect medium (Sigma), pH 7.2, supplemented
with 10 % FCS. Most of the isolates were characterized as
L. (V.) braziliensis by isoenzyme electrophoresis and mono-
clonal antibodies in the Departamento de Bioquimica e
Biologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio
de Janeiro, Brazil [19]. The promastigotes used in the ex-
periments were in the stationary phase of growth and had
no more than four passages in culture.
THP-1 monocytic cell line and cell culture
The monocytic cell line THP-1 (ATCC) was grown and
replicated every 4 days in RPMI 1640 supplemented with
5 % FCS, 100 UI/ml streptomycin, 2 mM L-glutamine,
11 mM sodium bicarbonate and maintained in a humidi-
fied atmosphere at 37 °C with 5 % CO2. The viability
was assessed by a dye exclusion test using 0.02 % trypan
blue in phosphate-buffered saline 0.01 M, pH 7.2 (PBS);
to test for infection, 2 × 105 cells in 500 μl in RPMI 1640
with 2 % FCS were distributed in each well of 24-well
culture plates in triplicate with sterile, round 13 mm
coverslips.
THP-1 monocytes were submitted to 20 ng/ml phorbol
12-myristate 13 acetate (PMA) for 24 h at 37 ° C, 5 % CO2
for differentiation into macrophages [20]. The non-adherent
cells were removed, the medium was replaced, and the cells
were maintained for 24 h in the same conditions. Infection
with Leishmania/macrophage (ratio of 10:1), using isolates
from CL, ML and DL of L. (V.) braziliensis, was performed
with or without stimulation with IGF-I (50 ng/ml) and
incubated at 33 °C, 5 % CO2. After 4 h, the plates were
washed with warm PBS to remove non-internalized para-
sites, and the RPMI 1640 medium with 2.0 % FCS and IGF-
I was replaced. After different incubation times, the super-
natant was collected and stored at -70 °C for evaluation of
arginase activity, and the coverslips were taken for intracel-
lular parasite counting.
Evaluation of intracellular parasite load
The coverslips removed from the plates were stained with
Giemsa dyes, and intracellular parasites were counted
under a light microscope (Carl Zeiss, Germany). For each
experimental condition, 600 cells and intracellular parasites
were counted by two independent observers, blinded for
experimental conditions. The data are presented as the
number of parasites per 100 cells.
Arginase activity
The cells and promastigotes were removed from the
cultures, lysed and submitted to arginase activity deter-
mination [21]. Briefly, to activate the arginase, 50 μl of
lysate was treated with the same volume of 5 mM
MnCl2, 25 mM Tris-HCl pH 7.4 at 56 °C for 10 min.
Then, 25 μl of 0.5 M L-arginine pH 9.7 was added to 25 μl
of the activated lysate and incubated at 37 °C for 60 min.
The reaction was stopped with 400 μl of H2SO4/H3PO4/
H2O (1/3/7, v/v/v). The urea concentration was measured at
540 nm in a spectrophotometer Multiskan MCC/340 P
version 2.20 plate reader (Labsystems, Vantaa, Finland) after
the addition of 25 μl of 9 % α-isonitrosopropiophenone in
100 % methanol and submitted to 100 °C for 45 min. One
unit of enzyme activity was defined as the amount of en-
zyme that catalyzes the formation of 1 μmol of urea per
minute.
Analyzes of circulation IGF-I and IGFBP3 levels
IGF-I and IGFBP3 assays were performed using the IMMU-
LITE® 2000 (DPC-Diagnostics Products Corporation, Los
Angeles, CA, USA). This procedure is an automated 2-site
sandwich immunoassay with a chemiluminescent immuno-
metric assay. It was configured and calibrated on an instru-
ment at Laboratório de Hormônio do Hospital das Clínicas
da Universidade de São Paulo, according to the manufac-
turer’s instructions.
Statistical analysis
Statistical analysis was performed using GraphPad Prism5
(GraphPad Software, Inc., San Diego, CA, USA). The
isolates results were submitted to ANOVA with post-hoc
Student-Newman Keuls test. An alpha error of 5 % (P =
0.05) was considered to determine statistical significance.
The IGF-I and IGFBP3 assay results were expressed as me-
dians and percentiles (25–75) and submitted to the
Kruskal-Wallis test with the Student Newman-Keuls post-
hoc test to statistically compare the groups.
Results
In this study, we initially evaluated the parasitism and
the arginase activity of the isolates of L. (V.) braziliensis
derived from patients presenting CL (n = 8), ML (n = 7)
or DL (n = 7).
We evaluated the parasites as amastigotes within human
monocytic cell line THP-1 in the presence or the absence
of the growth factor IGF-I. This cell line can be activated
by IGF-I [22]. Having perceived differences in the bio-
logical parameters in this approach, we then evaluated the
IGF-I and IGFBP3 serum levels in patients and in controls
living in the same endemic area.
The percentage of infected cells in basal conditions
(i.e. no IGF-I stimulus) indicated that the parasitism
tended to be lower with isolates of Leishmania coming
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from DL than from CL and ML cases (Fig. 1a). The para-
site load (number of amastigotes/100 infected cells) in the
basal conditions tended to be greater with parasites from
CL than ML and DL cases (Fig. 1b and Table 1). Evaluat-
ing the effect of IGF-I on the isolates as a whole in each
group, we observed no significant differences in the per-
centage of infection (Fig. 1a) or in the number of amasti-
gotes/100 cells (Fig. 1b and Table 1).
However, to further assess the effect of IGF-I in infections
and have a better view of the behavior of individual isolates,
we calculated the ratio of the individual parasite load in cul-
tures stimulated with IGF-I in relation to its basal culture
in which a ratio greater than 1.0 would indicate the positive
effect on parasite growth (Fig. 2). After a culture period of
48 h, we observed an increase in the parasitism ratio upon
IGF-I stimulus in 62.5 % (5 of 8) of the isolates from CL
cases, in 85.7 % (6 of 7) of the isolates from ML cases and
in only 42.8 % (3 of 7) from DL patients. Notably, the iso-
lates from the DL cases showed reduced growth in the
presence of IGF-I.
In the analysis of arginase activity, both basal and IGF-I-
stimulated levels were lower in those cells infected with
isolates from DL than in those from CL and ML (Fig. 3).
The above results suggest that IGF-I is beneficial or
deleterious depending on the isolates; therefore, we
analyzed whether IGF-I serum levels were altered in
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Fig. 1 Effect of IGF-I on parasitism in THP-1 with isolates of Leishmania
from patients with cutaneous (CL, n= 8), mucosal (ML, n= 7) or
disseminated (DL, n= 7) forms of the disease. THP-1 cells infected with
the isolates of Leishmania (V.) braziliensis were stimulated or not with
IGF-I (50 ng/ml) throughout the culture period of 48 h. Parasitism was
evaluated by optical microscopy and the result is represented as the
number of parasites per 100 cells (a). Parasite load ratio upon IGF-I-
stimuli and basal conditions in THP-1 cells infected with Leishmania
(b). Horizontal bar represents the mean value. Results representative
of two experiments with each isolate tested in triplicate
Table 1 Effect of IGF-I on parasitism in THP-1 with isolates of
Leishmania
Leishmania from CL ML DL
IGF-I (50 ng/ml) – + – + – +
Parasite isolates 124 107 139 199 255 180
78 87 146 148 110 133
449 455 73 73 33 33
140 145 177 182 36 28
135 161 108 126 122 125
412 365 38 45 33 34
85 106 106 136 38 30
153 133
THP-1 cells were infected with the isolates of L. (V.) braziliensis from patients
with cutaneous (CL, n = 8), mucosal (ML, n = 7) or disseminated (DL, n = 7)
forms of the disease and stimulated or not with IGF-I (50 ng/ml) throughout
the culture period of 48 h. Parasitism was evaluated by optical microscopy and
the result is represented as the number of parasites per 100 cells. Results
representative of two experiments with each isolate tested in triplicate
Fig. 2 Infection ratio of THP-1 cells infected with Leishmania isolates
from patients with different clinical presentations upon IGF-I stimulus.
Infection ratio between parasite load of cells upon IGF-I stimulus and
basal infection without stimulus. THP-1 cells were infected with Leishmania
isolates from CL (n= 8), ML (n= 7) or DL (n= 7) and maintained in culture
with or without IGF-I (50 ng/ml) for 48 h. Parasitism was assessed by
optical microscopy and the results expressed as number of
amastigotes/100 cells
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leishmaniasis patients presenting with different clinical
forms of the disease.
The clinical features of the studied patients are presented
in Tables 2 and 3. There were no significant differences in
the group distributions according to age (Table 2) and sex
(Table 3). The higher percentage of men than women in all
groups of patients likely reflects the epidemiological charac-
teristics of the transmission of infection with higher expos-
ure of the male to the insect bite due to their agricultural
activity, although sex-related biological factors cannot be
discarded.
The IGF-I and IGFBP3 serum levels were analyzed, and
the fact that the groups do not differ in age distribution
was important for these evaluations because these levels
vary considerably in different age ranges [23]. While pa-
tients with CL showed similar average levels of IGF-I com-
pared with control subjects, patients with ML and DL had
significantly lower levels than patients with CL (Fig. 4).
These results were similar when analyzing men and women
separately (data not shown). In contrast, IGFBP3 levels in
the serum of patients were similar between the studied
groups (data not shown).
Discussion
The pathogenesis of American tegumentary leishmania-
sis currently is considered multifactorial, due to not only
specific immune response [24] but also parasite diversity
[4, 17] and other factors related to the host [25, 26]. In
this scenario, we have been studying the role of IGF-I in
leishmaniasis mainly in vitro and in experimental models
of leishmaniasis. The role of IGF-I in human leishmania-
sis has not been established.
Based on our previous experimental data, IGF-I can
play a role in the progression of Leishmania (Leishmania)
amazonensis infection by (i) decreasing NO production in
macrophages and allowing parasite multiplication, (ii)
modulating immune responses by increasing TGF-β and
decreasing IFNγ production in promastigote infected
macrophages, and (iii) inducing apoptotic mimicry charac-
terized by exposure of phosphatidyl serine on amastigotes
but without leading to death [15, 16]. However, it is un-
known whether similar effects of IGF-I would occur in
other Leishmania species.
Because tegumentary leishmaniasis in Brazil is mostly
caused by L. (V.) braziliensis [1] and different biological
effects may occur upon IGF-I stimulus, we initially stud-
ied its effect on promastigotes. Focusing on the increase
of arginase activity of the parasite, which was seen as
main effect of IGF-I [16], we confronted more complex
outcomes that were dependent on Leishmania isolates,
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Fig. 3 Effect of IGF-I on arginase activity in THP-1 infected with
Leishmania isolated from patients with different clinical presentations.
THP-1 cells were infected with Leishmania isolates from CL (n= 8), ML
(n= 7) or DL (n= 7) and maintained in culture with or without IGF-I
(50 ng/ml) for 24 h. Representative result of two experiments (mean
± standard deviation). One unit of arginase activity = the amount of
enzyme that catalyzed the formation of 1 micromol urea/min. Result
is shown as: mU arginase/1 × 106 cells)
Table 2 Clinical profile of study patients with Leishmaniasis
Clinical Form
Parameters Cutaneous L Mucosal L Disseminated L Controls
Number 65 20 29 14
Age (years) 34 ± 10 43 ± 10 38 ± 12 30 ± 8
The age was expressed as mean ± standard deviation. See Methods for further
details. ANOVA test with the Student Newman-Keuls post-hoc test for statistical
comparison among groups. P > 0.05
Table 3 Gender distribution of American Tegumentary Leishmaniasis (ATL) patients
Clinical Form Sex OR 95 % CI P-value*
Male Female
Controls1,2,4 12 2
Cutaneous L1,3,5 55 10 1.1 0.21–5.63 10.9172
Mucosal L2,3,6 13 7 3.2 0.55–18.72 20.1779
3.0 0.95–9.26 30.0551
Disseminated L4,5,6 26 2 0.5 0.06–3.68 40.4572
0.4 0.09–2.07 50.2768
0.1 0.02-0.79 60.0148
*P value analyzed by the χ2 test. Note: Odds ratios (OR) and χ2 tests were performed with groups that bear the same number in superscript; the respective odds
ratio, 95 % confidence interval (CI), and P-value for each comparison has the same number in superscript. No statistically significant differences were found
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whether coming from patients with CL, ML or DL. IGF-
I induced higher basal arginase activity in L. (V.) brazi-
liensis promastigote isolates from CL and DL but not in
ML. Conversely, in Leishmania isolate from ML the
arginase activity was already increased in basal condi-
tions [17]. In the present study, we analyzed the effect of
IGF-I on intracellular amastigotes in sequence.
The intracellular amastigote growth was evaluated here
using human macrophage cell line THP-1 rather than
macrophages derived from peripheral blood monocytes to
avoid the variation in cellular response that would occur if
obtained from different individuals. IGF-I induced an in-
crease in parasitism in CL and ML isolates but a decrease
in parasitism in DL isolates. In CL and ML these data
suggest that the presence of IGF-I may contribute to the
persistence of the parasite in the skin. In DL isolates, basal
arginase activity was also lower than that of CL. However,
arginase activity was similar with and without IGF-I
stimulus, leaving mechanisms that need to be further
explored.
To proceed with the study of the involvement of IGF-I
in different clinical manifestations, IGF-I and IGFBP3
serum levels were evaluated in patients with CL, ML
and DL. In CL, both of these levels were similar to those
in healthy controls, while in ML and DL, both levels
were decreased. Altogether, these data indicate that IGF-I
cannot be interpreted as having similar effects in patients
presenting different clinical manifestations and that the ef-
fects may encompass healing and inflammatory processes
beyond parasite growth.
American tegumentary leishmaniasis is characterized
by an intense inflammation with a high production of
tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ),
molecules that are necessary to protect the host against
Leishmania but can also cause tissue damage even with a
scarce number of parasites in the lesions [25, 27]. In the
early phase of the disease when patients have a small cuta-
neous lesion or when is evolving to heal [28], this T helper
type 1 immune response is known to be down modulated
[29]. IGF-I is known to be increased in the initial phase of
skin injury because this molecule is necessary for epider-
mis maintenance [30, 31], which would occur also in CL.
In CL, because IGF-I is suggested by the present findings
to have a parasite growth promoting effect on Leishmania
isolates and has its serum level maintained in the level of
controls, IGF-I would probably contribute to the progres-
sion of parasite growth and establishment of Leishmania
in the host skin.
Cutaneous ulcer is the first lesion of tegumentary leish-
maniasis that later can be complicated by the appearance
of mucosal or disseminated disease. After the initial phase
of L. (V.) braziliensis infection, a very strong Th1 immune
response occurs that is associated with a decrease in IL-10
production [32]. IFN-γ and TNF-α are also produced in
even higher concentrations in ML patients [33], and this
increased production of cytokines may relate to the
lower level of IGF-I in patients with ML observed in
the present study.
In DL patients, a slight decrease in IFN-γ production
was observed when analyzing peripheral blood mono-
nuclear cells, which may result from the migration of ac-
tivated T cells to the multiple lesions and to the mucosal
tissue because up to 40 % of DL patients have mucosal
disease [34]. In DL, IFN-γ production is still high that
may relate to the decreased IGF-I serum levels found
here in this form of the disease.
IGF-I was shown to decrease vascular inflammatory
process in mouse model of atherosclerosis [14]. Because
the pathogenesis of American tegumentary leishmaniasis
is based on an exaggerated immune response [35, 36], a
decrease in IGF-I in ML and DL may contribute to the
persistence of the inflammatory response and further on
the delayed healing of the lesion.
Having pathogenic mechanism involving IGF-I in
mind we can speculate the use of IGF-I to stimulate
healing and control of inflammation in chronic and se-
vere cases of ATL where IGF-I level is decreased. There
are studies on IGF-I use in other dermatological lesions.
In diabetes mellitus ulcer it is suggested that the healing
is delayed due to a decrease in IGF-I level in the skin
[12] and some approaches have been tried. In diabetes
mellitus patients the skin ulcer healed with an increase
in local IGF-I level upon the use of hyperbaric oxygen
therapy [37]. In experimental diabetes model local use of
IGF-I cream has also improved the healing [38]. In ATL
IGF-I may increase the parasite growth but it would be in
the tissue environment where strong Th1-type immune
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Fig. 4 IGF-I serum levels in patients with American Tegumentary
Leishmaniasis. Serum of patients with CL (n=65), ML (n=20), DL
(n=29), and healthy subjects were measured by chemiluminescent
immunometric assay (IMMULITE® 2000-DPC). The horizontal bar
represents the median value. Kruskal-Wallis test with the Dunn
contrast post-test: *CL in relation to DL; Controls in relation to DL
and ML P < 0.05; **CL in relation to ML P < 0.001
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response is present and thus the parasite growth would be
restrained.
Conclusions
In the present study, analyzing the effect of IGF-I on
amastigotes of Leishmania isolates from patients and
evaluating the IGF-I serum levels, we observed results
that suggest IGF-I affecting both parasites and healing
and inflammatory processes with IGF-I being modulated
differently in distinct clinical forms of ATL. We suggest
that in the initial phase of the disease, there are main-
tained levels of IGF-I that contribute to downregulation
of the immune response and for parasite growth/persist-
ence. In the late phase of the infection, with the decrease
in IGF-I levels it would allow mainly the persistence of a
tissue damage.
In view of potential role of IGF-I in the pathogenesis
of ATL we can speculate on therapeutic procedures tak-
ing into account the local IGF-I level.
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